Avalo Therapeutics Down Nearly 40%, On Pace for Largest Percent Decrease Since June 2023 -- Data Talk
Dow Jones2026/10/22 15:05Avalo Therapeutics Inc. (AVTX) is currently at $7.36, down $4.90 or 39.97%
--Would be lowest close since July 30, 2025, when it closed at $6.66
--On pace for largest percent decrease since June 26, 2023, when it fell 88.69%
--Currently down two consecutive days; down 40.45% over this period
--Worst two day stretch since the two days ending Sept. 18, 2023, when it fell 42.6%
--Down 51.99% month-to-date
--Down 59.47% year-to-date; on pace for worst year since 2023, when it fell 99.25%
--Down 99.96% from its all-time closing high of $20793.61 on Feb. 27, 2019
--Down 58.93% from 52 weeks ago (Oct. 23, 2025), when it closed at $17.92
--Down 67.82% from its 52-week closing high of $22.87 on May 7, 2026
--Would be a new 52-week closing low
--Traded as low as $6.85; lowest intraday level since July 31, 2025, when it hit $6.57
--Down 44.13% at today's intraday low; largest intraday percent decrease since June 26, 2023, when it fell as much as 88.69%
All data as of 11:02:46 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 22, 2026 11:05 ET (15:05 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
